Nifty
Sensex
:
:
14491.75
48472.03
180.95 (1.26%)
588.65 (1.23%)

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 532321 | NSE: CADILAHC

499.70
12-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  517.75
  •  532.00
  •  494.35
  •  514.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  26881035
  •  139007.61
  •  532.00
  •  318.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 51,182.01
  • 27.72
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 58,216.41
  • 0.70%
  • 4.17

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.90%
  • 6.16%
  • FII
  • DII
  • Others
  • 5.23%
  • 10.91%
  • 1.92%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 8.62
  • 6.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.59
  • 3.60
  • -0.34

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.91
  • -9.50
  • -12.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.33
  • 25.02
  • 20.51

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.39
  • 4.63
  • 3.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.95
  • 16.15
  • 13.24

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
3,795.60
3,638.10
4.33%
3,820.00
3,366.60
13.47%
3,639.90
3,496.30
4.11%
3,752.10
3,732.80
0.52%
Expenses
2,988.70
2,940.30
1.65%
2,956.60
2,731.00
8.26%
2,824.50
2,837.60
-0.46%
2,960.90
2,922.00
1.33%
EBITDA
806.90
697.80
15.63%
863.40
635.60
35.84%
815.40
658.70
23.79%
791.20
810.80
-2.42%
EBIDTM
21.26%
19.18%
22.60%
18.88%
22.40%
18.84%
14.01%
14.01%
Other Income
27.50
20.10
36.82%
27.50
26.90
2.23%
22.50
22.60
-0.44%
44.30
38.40
15.36%
Interest
26.80
80.50
-66.71%
45.70
89.70
-49.05%
67.70
89.10
-24.02%
82.50
77.30
6.73%
Depreciation
180.40
174.10
3.62%
179.00
172.30
3.89%
176.80
171.60
3.03%
178.50
155.60
14.72%
PBT
627.20
457.10
37.21%
534.20
122.40
336.44%
593.40
393.90
50.65%
522.00
605.90
-13.85%
Tax
114.70
92.70
23.73%
110.60
39.50
180.00%
123.50
79.10
56.13%
108.50
126.70
-14.36%
PAT
512.50
364.40
40.64%
423.60
82.90
410.98%
469.90
314.80
49.27%
413.50
479.20
-13.71%
PATM
13.50%
10.02%
11.09%
2.46%
12.91%
9.00%
7.11%
7.11%
EPS
5.15
3.65
41.10%
4.62
1.05
340.00%
4.43
2.96
49.66%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
15,007.60
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
Net Sales Growth
5.44%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
 
Cost Of Goods Sold
8,510.80
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
Gross Profit
6,496.80
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
GP Margin
43.29%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
Total Expenditure
11,730.70
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
Power & Fuel Cost
-
268.80
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
% Of Sales
-
1.89%
1.88%
1.89%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
Employee Cost
-
2,389.80
2,099.40
1,825.20
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
% Of Sales
-
16.77%
15.95%
15.27%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
Manufacturing Exp.
-
1,468.00
1,334.70
1,211.40
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
% Of Sales
-
10.30%
10.14%
10.13%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
General & Admin Exp.
-
909.20
701.50
504.60
466.00
432.70
326.80
365.70
342.20
271.90
234.90
% Of Sales
-
6.38%
5.33%
4.22%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
Selling & Distn. Exp.
-
1,209.50
914.60
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
% Of Sales
-
8.49%
6.95%
8.49%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
Miscellaneous Exp.
-
984.30
748.50
687.00
502.60
561.80
417.40
310.30
157.40
185.90
710.70
% Of Sales
-
6.91%
5.69%
5.75%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
EBITDA
3,276.90
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
EBITDA Margin
21.83%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
Other Income
121.80
117.10
208.50
113.30
147.10
116.60
57.20
58.00
38.40
53.00
22.80
Interest
222.70
341.80
195.80
91.10
63.10
52.80
67.90
90.20
168.70
182.70
69.90
Depreciation
714.70
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
PBT
2,276.80
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
Tax
457.30
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
Tax Rate
20.09%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
PAT
1,819.50
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
PAT before Minority Interest
1,824.50
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
Minority Interest
5.00
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
PAT Margin
12.12%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
PAT Growth
46.58%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
 
EPS
17.77
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37
6.95

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
Non-Current Liabilities
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
Secured Loans
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
Unsecured Loans
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
Long Term Provisions
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
Current Liabilities
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
Trade Payables
2,031.00
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
Other Current Liabilities
2,139.60
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
Short Term Borrowings
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
Short Term Provisions
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
Total Liabilities
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
Net Block
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
Gross Block
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
Accumulated Depreciation
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
Non Current Assets
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
Capital Work in Progress
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
Non Current Investment
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
Long Term Loans & Adv.
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
Other Non Current Assets
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
Current Assets
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
Current Investments
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
Inventories
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
Sundry Debtors
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
Cash & Bank
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
Other Current Assets
1,085.50
496.00
520.70
80.00
358.90
311.50
323.50
345.90
332.00
253.00
Short Term Loans & Adv.
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
206.20
Net Current Assets
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
Total Assets
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,505.40
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
PBT
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
Adjustment
1,182.70
539.10
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
Changes in Working Capital
129.40
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
Cash after chg. in Working capital
2,807.50
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.40
7.80
-30.80
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
Net Fixed Assets
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
Net Investments
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
Others
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
Cash from Financing Activity
-1,094.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
Net Cash Inflow / Outflow
398.90
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
Opening Cash & Equivalents
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
Closing Cash & Equivalent
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
ROA
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
ROE
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
ROCE
10.02%
15.89%
18.26%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
Fixed Asset Turnover
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
1.75
Receivable days
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
47.97
Inventory Days
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
60.83
Payable days
68.68
72.33
71.11
74.18
67.53
55.78
50.51
43.54
49.87
64.40
Cash Conversion Cycle
98.94
97.21
75.95
62.42
50.28
60.73
65.09
74.05
72.45
44.40
Total Debt/Equity
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
Interest Cover
5.38
13.17
26.38
26.55
40.75
22.29
11.45
5.79
5.35
13.05

News Update:


  • Zydus Cadila gets USFDA's approval to market Macitentan Tablets
    8th Apr 2021, 09:20 AM

    The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Cadila seeks DCGI nod for use of hepatitis drug for COVID-19 treatment
    5th Apr 2021, 11:56 AM

    Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name 'PegiHep' has shown promising results in treating COVID-19

    Read More
  • Zydus Cadila gets tentative approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
    25th Mar 2021, 13:08 PM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus makes Remdac more affordable at Rs 899
    24th Mar 2021, 15:12 PM

    This move to further revise the prices will go a long way in helping patients during these critical times

    Read More
  • Zydus Cadila gets final approval from USFDA to market Nortriptyline Hydrochloride Capsules
    25th Feb 2021, 11:46 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets final approval from USFDA to market Droxidopa Capsules
    19th Feb 2021, 11:31 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Cadila Healthcare reports 41% rise in Q3 consolidated net profit
    6th Feb 2021, 10:56 AM

    Total consolidated income of the company increased by 4.51% at Rs 3,823.10 crore for Q3FY21

    Read More
  • Zydus Cadila completes large scale enrolment for two Phase III trials of Desidustat
    5th Feb 2021, 10:19 AM

    The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis

    Read More
  • Zydus Cadila completes Phase -I trials of ZY19489-A single dose cure for Malaria
    4th Feb 2021, 11:24 AM

    ZY19489 has the potential to be a single-dose cure for P. falciparum and P. vivax malaria due to its novel mechanism of action, rapid parasites killing activity

    Read More
  • Zydus Cadila granted ‘Orphan Drug Designation’ by USFDA
    28th Jan 2021, 11:48 AM

    The company has been granted ‘Orphan Drug Designation’ to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis

    Read More
  • Zydus Cadila gets positive results from phase 2(b) studies of COVID-19 drug Desidustat in Mexico
    25th Jan 2021, 12:13 PM

    In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidates Desidustat in the management of COVID-19

    Read More
  • Zydus Cadila gets final approval from USFDA for Liothyronine Sodium Tablets
    23rd Jan 2021, 11:18 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More
  • Zydus Cadila gets DCGI’s nod to start Phase III Clinical Trial of ZyCoV-D- fully indigenously developed vaccine
    4th Jan 2021, 08:53 AM

    The company will now be initiating Phase III clinical trial in around 30,000 volunteers

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.